Inte Conal Application No PCT/EP2004/051550

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/4178 A61K31/4184 C07D403/04 C07D409/06 A61K31/41

C07D403/10

C07D257/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

 $\begin{array}{ccc} \text{Minimum documentation searched (classification system followed by classification symbols)} \\ IPC & 7 & A61K & C07D \end{array}$ 

	the design of the second state of the second s	and decomposite are behinded to the fields of	parehad
Documentat	ion searched other than minimum documentation to the extent that	Such documents are included. In the helps se	Salched
Electronia de	ata base consulted during the international search (name of data b	ase and, where practical search terms used	·
	ternal, WPI Data, CHEM ABS Data	ase and, whole practical, societies terms dece	,
ELO-111	ternar, wri Data, Chem Abs Data		
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the r	elevant passages	Relevant to claim No.
X	WO 00/61537 A (NICOX SA (FR)) 19 October 2000 (2000-10-19) page 2, paragraph 2 page 3, paragraph 3 page 6, paragraph 2: losartan page 7, formula (I) page 38, paragraph 1 example 12		1-14
Y	WO 03/013499 A (NICOX SA (FR)) 20 February 2003 (2003-02-20) page 1, paragraph 1 - paragraph formula (I) compounds (V)-(IX)	2	1-14
χ Furt	her documents are listed in the continuation of box C.	Patent family members are listed	in annex.
"A" docum consider "E" earlier filling of "L" docum which citatio "O" docum other	ategories of cited documents:  ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another on or other special reason (as specified) lent referring to an oral disclosure, use, exhibition or means ent published prior to the international filling date but than the priority date claimed	"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family	
Date of the	actual completion of the International search	Date of malling of the international sea	arch report
1	7 January 2005	2 2. 02. 2005	
Name and	mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL – 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo ni,  Fax: (+31-70) 340-3016	Authorized officer Cortés, J	

Intermonal Application No PCT/EP2004/051550

MCINTYRE ET AL.: "Losartan, an Orally Active Angiotensin (AT1) Receptor Antagonist: A Review of Its Efficacy and Safety in Essential Hypertension" PHARMACOL. THER., vol. 74, no. 2, 1997, pages 181-194, XP002262197 the whole document  EP 0 955 294 A (SMITHKLINE BEECHAM CORP (UK)) 10 November 1999 (1999-11-10) page 1, paragraph 1 examples 44,56,57,69,88 claims  HEDNER T ET AL: "A COMPARISON OF THE ANGIOTENSIN II ANTAGONISTS VALSARTAN AND LOSARTAN IN THE TREATMENT OF ESSENTIAL HYPERTENSION" AMERICAN JOURNAL OF HYPERTENSION, NEW YORK, NY, US, vol. 12, no. 4, April 1999 (1999-04), pages 414-417, XP000866169 the whole document	1-14 1-14
MCINTYRE ET AL: "Losartan, an Orally Active Angiotensin (AT1) Receptor Antagonist: A Review of Its Efficacy and Safety in Essential Hypertension" PHARMACOL. THER., vol. 74, no. 2, 1997, pages 181-194, XP002262197 the whole document  EP 0 955 294 A (SMITHKLINE BEECHAM CORP (UK)) 10 November 1999 (1999-11-10) page 1, paragraph 1 examples 44,56,57,69,88 claims  HEDNER T ET AL: "A COMPARISON OF THE ANGIOTENSIN II ANTAGONISTS VALSARTAN AND LOSARTAN IN THE TREATMENT OF ESSENTIAL HYPERTENSION" AMERICAN JOURNAL OF HYPERTENSION, NEW YORK, NY, US, vol. 12, no. 4, April 1999 (1999-04), pages 414-417, XP000866169 the whole document	1-14
Active Angiotensin (AT1) Receptor Antagonist: A Review of Its Efficacy and Safety in Essential Hypertension" PHARMACOL. THER., vol. 74, no. 2, 1997, pages 181-194, XP002262197 the whole document  EP 0 955 294 A (SMITHKLINE BEECHAM CORP (UK)) 10 November 1999 (1999-11-10) page 1, paragraph 1 examples 44,56,57,69,88 claims  HEDNER T ET AL: "A COMPARISON OF THE ANGIOTENSIN II ANTAGONISTS VALSARTAN AND LOSARTAN IN THE TREATMENT OF ESSENTIAL HYPERTENSION" AMERICAN JOURNAL OF HYPERTENSION, NEW YORK, NY, US, vol. 12, no. 4, April 1999 (1999-04), pages 414-417, XP000866169 the whole document	1-14
(UK)) 10 November 1999 (1999-11-10) page 1, paragraph 1 examples 44,56,57,69,88 claims  HEDNER T ET AL: "A COMPARISON OF THE ANGIOTENSIN II ANTAGONISTS VALSARTAN AND LOSARTAN IN THE TREATMENT OF ESSENTIAL HYPERTENSION" AMERICAN JOURNAL OF HYPERTENSION, NEW YORK, NY, US, vol. 12, no. 4, April 1999 (1999-04), pages 414-417, XP000866169 the whole document	
ANGIOTENSIN II ANTAGONISTS VALSARTAN AND LOSARTAN IN THE TREATMENT OF ESSENTIAL HYPERTENSION" AMERICAN JOURNAL OF HYPERTENSION, NEW YORK, NY, US, vol. 12, no. 4, April 1999 (1999-04), pages 414-417, XP000866169 the whole document	1-14
ED 1 212 270 A CTAVEDA CHEMICAL INDUSTRIES	
EP 1 312 379 A (TAKEDA CHEMICAL INDUSTRIES LTD (JP)) 21 May 2003 (2003-05-21) the whole document	1-14
"TELMISARTAN" DRUGS OF THE FUTURE, BARCELONA, ES, vol. 22, no. 10, 1997, pages 1112-1116, XP009008343 ISSN: 0377-8282 the whole document	1-14
"OLMESARTAN MEDOXOMIL CS-866 BENEVAS ANTIHYPERTENSIVE ANGIOTENSIN AT ANTAGONIST" DRUGS OF THE FUTURE, BARCELONA, ES, vol. 25, no. 11, November 2000 (2000-11), pages 1217-1218, XP009030725 ISSN: 0377-8282 the whole document	1-14
HEDNER T: "THE CLINICAL PROFILE OF THE ANGIOTENSIN II RECEPTOR BLOCKER EPROSARTAN" JOURNAL OF HYPERTENSION, CURRENT SCIENCE, PHILADELPHIA, PA, US, vol. 20, no. SUPPL 5, 2002, pages S33-S38, XP008011504 ISSN: 0263-6352 the whole document	1-8
	ISSN: 0377-8282 the whole document  "OLMESARTAN MEDOXOMIL CS-866 BENEVAS ANTIHYPERTENSIVE ANGIOTENSIN AT ANTAGONIST" DRUGS OF THE FUTURE, BARCELONA, ES, vol. 25, no. 11, November 2000 (2000-11), pages 1217-1218, XP009030725 ISSN: 0377-8282 the whole document  HEDNER T: "THE CLINICAL PROFILE OF THE ANGIOTENSIN II RECEPTOR BLOCKER EPROSARTAN" JOURNAL OF HYPERTENSION, CURRENT SCIENCE, PHILADELPHIA, PA, US, vol. 20, no. SUPPL 5, 2002, pages S33-S38, XP008011504 ISSN: 0263-6352



Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Claims Nos.:     because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of Invention is lacking (Continuation of Item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As a result of the prior review under R. 40.2(e) PCT, all additional fees are to be refunded.
As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report Is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

- 1. claims: 1-14 (partly)
- 2. claims: 1-14 (partly)
  - compounds wherein R is (II) and R1 is (IIb) (valsartan related compounds)
- 3. claims: 1-14 (partly)
  - compounds wherein R is (II) and R1 is (IIc) (candesartan related compounds)
- 4. claims: 1-14 (partly)
- 5. claims: 1-14 (partly)
  - compounds wherein R is (II) and R1 is (IIe) (olmesartan related compounds)
- 6. claims: 1-14 (partly)
  - compounds wherein R is (III) (eprosartan related compounds)

information on patent family members

Intentional Application No PCT/EP2004/051550

				1017212	004/031330
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0061537	A	19-10-2000	IT AU BR CA CN WO EP HU JP MX NO NZ PL RU ZA	MI990753 A1 4400100 A 0009702 A 2370412 A1 1354740 T 0061537 A2 1169294 A2 0203378 A2 2002541233 T PA01010210 A 20014927 A 514267 A 350777 A1 2237657 C2 200108127 A	13-10-2000 14-11-2000 08-01-2002 19-10-2000 19-06-2002 19-10-2000 09-01-2002 28-01-2003 03-12-2002 18-09-2002 13-12-2001 25-06-2004 10-02-2003 10-10-2004 03-01-2003
WO 03013499	Α	20-02-2003	IT WO	MI20011744 A1 03013499 A2	10-02-2003 20-02-2003
EP 0955294	A	10-11-1999	EPT AAUUANNYEE DE DE DE DE DE DE ESSIRKKUEE LIPPRRUAXLOZHL	0955294 A2 190051 T 250587 T 633322 B2 5690190 A 2018438 A1 1048038 A ,B 1079649 A ,B 2232 A 10075018 I1 69033469 T2 69034103 D1 69034103 T2 403159 T3 955294 T3 0403159 A2 2142789 T3 2207091 T3 102610 B1 3033452 T3 1025315 A1 1012384 A1 55011 A2 20000297 A1 902140 A1 94698 A 2036046 C 3115278 A 7068223 B 165837 B1 90562 A9 21896 A1 21109 A 300006 I1 902632 A ,B, 233997 A 27592 A 285591 A1	10-11-1999 15-03-2000 15-10-2003 28-01-1993 10-01-1991 14-12-1990 26-12-1990 22-12-1993 18-04-2003 21-09-2000 06-04-2000 07-09-2000 30-10-2003 15-07-2004 14-08-2000 02-02-2004 19-12-1990 01-05-2000 16-05-2004 15-01-1999 29-09-2000 23-07-2004 24-11-2000 29-04-1991 13-12-2000 02-01-1991 31-07-1994 28-03-1996 16-05-1991 26-07-1995 18-02-1999 05-06-2000 01-04-1991 31-01-1994 03-07-2000 17-12-1990 26-04-1991 31-01-1994 03-07-2000 17-12-1990 26-04-1991 31-08-1993 25-03-1991

Information on patent family members

# Inte onal Application No PCT/EP2004/051550

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0955294 A		PL 166669 B1 PL 166722 B1 PT 94377 A ,B SG 52330 A1 US 5418250 A US 5185351 A ZA 9004579 A ZW 9490 A1	30-06-1995 30-06-1995 20-03-1991 28-09-1998 23-05-1995 09-02-1993 26-06-1991 31-10-1990
EP 1312379 A	21-05-2003	AU 8013501 A CA 2420055 A1 EP 1312379 A1 WO 0215935 A1 JP 2002138054 A US 2003187038 A1	04-03-2002 31-01-2003 21-05-2003 28-02-2002 14-05-2002 02-10-2003